ERBB2 and breast cancer: Also importantly, vaccines based on the AE37 peptide, which is derived from the intracellular HER2 portion fused with the MHC-II invariant chain li-key, have demonstrated safety and effectiveness in decreasing disease recurrence in selected breast cancer patients.